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Phosphatase of Regenerating Liver-3 (PRL-3) is a small protein tyrosine phosphatase considered an appealing therapeutic cancer target due to
its involvement in metastatic progression. However, despite its importance, the direct molecular targets of PRL-3 action are not yet known. Here
we report the identification of Ezrin as a specific and direct cellular substrate of PRL-3. In HCT116 colon cancer cell line, Ezrin was identified
among the cellular proteins whose phosphorylation level decreased upon ectopic over-expression of wtPRL-3 but not of catalytically inactive
PRL-3 mutants. Although PRL-3 over-expression in HCT116 cells appeared to affect Ezrin phosphorylation status at both tyrosine residues and
Thr567, suppression of the endogenous protein by RNA interference pointed to Ezrin-Thr567 as the residue primarily affected by PRL-3 action.
In vitro dephosphorylation assays suggested Ezrin-Thr567 as a direct substrate of PRL-3 also proving this enzyme as belonging to the dual
specificity phosphatase family. Furthermore, the same effect on levels of pThr567, but not on pTyr residues, was observed in endothelial cells
pointing to Ezrin-pThr567 dephosphorylation as a mean through which PRL-3 exerts its function in promoting tumor progression as well as in the
establishment of the new vasculature needed for tumor survival and expansion.
© 2007 Elsevier B.V. All rights reserved.Keywords: PTP; Substrate identification; Phosphorylation; ERM proteins; RNA interference1. Introduction
Modulation of the phosphorylation state of proteins by the
coordinated action of kinases and phosphatases is a key regu-
latory mechanism of many eukaryotic cellular processes. The
protein tyrosine phosphatase (PTP) superfamily of phosphatases
includes a large group of enzymes important for the regulation of
a wide variety of cellular mechanisms including signal
transduction, cell cycle, differentiation, cellular transformation
as well as adhesion and motility [1,2]. Among them, increasing
evidence is accumulating suggesting that PRL tyrosine phos-
phatases (Phosphatase of Regenerating Liver-1, -2 and -3) play a
potentially pathogenic role in human malignancy and, above all,
PRL-3 could be considered an appealing therapeutic cancer
target due to its involvement in processes of cell motility and
invasion determining metastatic progression [3]. Among normal⁎ Corresponding author. Tel.: +39 06 91093230; fax: +39 06 91093654.
E-mail address: licia_tomei@merck.com (L. Tomei).
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doi:10.1016/j.bbamcr.2007.11.004adult human tissues, PRL-3 mRNA is expressed primarily in
skeletal muscle and heart, with lower expression levels in
pancreas, spleen, lung and testis [4,5] but little is currently
known about its physiological role in these tissues. In mouse, the
presence of PRL-3 in the differentiated epithelial cells of the
villus – but not in the proliferating cryptic cells – suggests that
PRL-3 may contribute to the differentiation of epithelial cells in
the small intestine [6]. In addition, a role in cardiac functions is
indicated by the observation that PRL-3 appears to be involved
in the modulation of intracellular calcium mobilization in
response to Angiotensin II [4].
In the last few years, evidence has accumulated for the
association of PRL-3 with oncogenic states and several
indications have linked its expression to human colon cancer
progression andmetastasis. The first data came from the analysis
of global gene-expression profiling of metastatic colorectal
cancers (CRC) which showed that PRL-3 is selectively over-
expressed in metastatic CRC cells with lower levels in non-
metastatic tumors and normal colorectal epithelium [7]. PRL-3
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lesions irrespective of the target organ [8,9]. PRL-3 expression
has also been reported in a Hodgkin's lymphoma cell line [10],
melanomas, liver, ovarian, breast and gastric cancers where its
presence seems to have an important role in the acquisition of
metastatic potential of tumor cells [11,12]. PRL-3 might also be
considered as a good molecular marker of tumor aggressive-
ness due to its expression in primary cancers as predictor of
metastasis [13,14].
Consistent with a role of PRL-3 over-expression in metas-
tasis, its ectopic expression in different cell types is correlated
with the induction of metastatic phenotypes, such as invasion
and motility capabilities [11,15,16]. On the contrary, its transient
down-regulation by RNA interference has an opposite effect [9].
These data are corroborated by in vivo data where PRL-3 over-
expression promotes experimental metastasis in mice [11,15,16]
while its down-regulation in human colon cancer cells abrogates
their metastatic potential [9,17]. A possible role of PRL-3 in
tumor-related angiogenesis has also been suggested by data
correlating PRL-3 expression with the genesis of new vascu-
lature [18] and by evidences showing that some metastatic
tumors sprout and grow into well-established blood vessels [16].
Recently, Fiordalisi et al. [19] demonstrated that PRL-3
modulates small GTPases of the Rho family and activates the
serum response element (SRE) transcription factor in a Rho-
dependent manner, suggesting not only a direct involvement of
this phosphatase in cytoskeleton modeling but also a role in the
transcriptional regulation of target genes. Liang et al. [20] found
that PRL-3 ectopic expression causes a down-regulation of Csk
level leading to a more active form of Src kinase. This activation
triggers several signal pathways culminating in the phosphor-
ylation Erk1/2, STAT3, and p130Cas which are responsible for
cell proliferation and invasion promotion. However, the only
PRL-3 interacting protein currently known is integrin α1 [21]
and direct targets of PRL-3 action have not been identified yet.
Here we report the identification of Ezrin as a specific target of
PRL-3: Ezrin emerged among the cellular proteins whose
phosphorylation level changed upon either ectopic over-expres-
sion of the PRL-3 protein or down-regulation of the endogenous
PRL-3 mRNA by RNA interference. Although PRL-3 over-
expression in the HCT116 colon cancer cell line appeared to
affect Ezrin phosphorylation status at both tyrosine residues and
Thr567, silencing experiment, combined to in vitro depho-
sphorylation assays, suggested that PRL-3 specifically acts on
Ezrin-pThr567. Furthermore, the same effect on pThr567, but not
on pTyr residues, was observed in endothelial cells, where ex-
pression of endogenous PRL-3 protein was enhanced by PMA
treatment, pointing to pThr567 as the specific and possibly direct
target of PRL-3 on Ezrin.
2. Materials and methods
2.1. Cells
HCT116 from ATCC were cultured at 37 °C/5%CO2 in McCoy's medium
(Invitrogen), supplemented with 10%FCS, antibiotics (streptomycin and penicillin
100 U/ml) and L-Glutamine 2 mM. HUVEC (Human Umbilical Vein Endothelial
Cells pooled from Lonza) were grown in EGM bullet kit (Lonza).2.2. Antibodies
Anti-human Ezrin (clone 3C12), α-GAPDH and α-tubulin were obtained
from Sigma. Anti-Phosphotyrosine (clone 4G10) andα-Phosphotyrosine (4G10)
agarose-conjugate were from Upstate. Anti-PhosphoEzrin(Thr567) and Phos-
phoEzrin(Tyr353) were from Cell Signaling. Anti-PhosphoEzrin(Tyr145) was
from Santa-Cruz Ltd. Peroxidase-conjugated secondary antibodies were pur-
chased from Sigma. A polyclonal antibody directed against PRL-3 was obtained
in rabbit using as antigen the PRL-3 protein lacking the C-terminal 4 residues
expressed in E. coli. Anti-Flag M2 Affinity gel freezer-Safe was from Sigma.
2.3. Plasmids
The wild-type PRL-3 coding sequence (NM 032611) was amplified by PCR
from a skeletal muscle cDNA library (Clontech) and inserted into BamHI and
EcoRI sites of the pcDNA3 vector (Invitrogen) giving rise to the construct
pCDwtPRL-3. The constructs pCDPRL-3(D72A) and pCDPRL-3(D72A/
C104S) were derived by site directed mutagenesis from pCDwtPRL-3 and
contained the following mutations: pCDPRL-3(D72A), replacement of GAT
codon for D72 with GCT (coding for A); pCDPRL-3(D72A/C104S), replace-
ment of GAT codon for D72 with GCT (coding for A) and replacement of TGC
for C104 with TCC (coding for S). For construction of pCD-FlagPRL-3, a DNA
sequence coding for the Flag epitope (MDYKDDDDK) followed by aGSGS link
was inserted by PCR at the N-terminus of the PRL-3 sequence in the plasmid
pCDwtPRL-3. Constructs were confirmed by DNA sequencing.
2.4. DNA transfection
HCT116 cells were transfected with pCD-PRL-3 plasmids or empty vector
usingLipofectamine 2000 (Invitrogen) as recommended by themanufacturer. Cells
were incubated 4 h at 37 °C/5%CO2 after which time cells were detached by
Trypsin-EDTA treatment, viable cells were counted with Guava and seeded for 24,
48 and 72 h incubation (37 °C/5%CO2). Before collection, cells were treated with
SodiumorthoVanadate andH2O2 0.1mMfor 30min at 37 °C,with the exception of
those transfected with the pCD-FlagPRL-3 plasmid. Cells transfected for the
expression of wtPRL-3 and mutant proteins were suspended in lysis buffer (Tris
20 mM, pH 7.5, NaCl 100 mM, Triton 1%, Glycerol 10%, EDTA 1 mM, Okadaic
acid1 μM (Calbiochem), Sodium Pyrophosphate 10 mM, NaF 20 mM, Iodoacetic
acid 5 mM (Sigma), DTT 1 mM, Sodium orthoVanadate 0.1 mM, Complete
(Roche)) and incubated 30 min on ice. Cells over-expressing FlagPRL-3 were
lysed in Tris 20 mM, pH 7.5, NaCl 100 mM, Triton 1%, Glycerol 10%, EDTA
1 mM, TCEP 1mM, DPTA 1 mM, and Complete. Protein concentrations in the
extracts were determined by Bradford method assay (BIO-RAD) and the presence
of PRL-3 confirmed by western blot using horseradish peroxidase-conjugated
secondary antibodies (Pierce) and ECL detection system (Amersham).
2.5. Mono-dimensional gel electrophoresis and mass spectrometry
Equal amounts of total protein extracts form mock- or PRL-3-transfected
cells were resolved by SDS-PAGE. The gels were initially incubated with Pro-Q
Diamond (Molecular Probes) for phospho-protein staining followed by des-
taining and incubation with SYPRO Ruby stain (Molecular Probe) for total
protein visualization, as recommended by the manufacturer. Detection was
performed on a Thyphoon 9410 (Amersham) using excitation/emission wave-
lengths as recommended by the manufacturer. For the identification of Ezrin,
protein bands were excised from mono-dimensional gel using the ProXcision
spot picker (Perkin Elmer Instruments, Shelton, CT, USA). Excised spots were
digested with Multiprobe liquid handler (Perkin Elmer Instruments). Gel plugs
were first washed with 100 mM ammonium bicarbonate for 5 min, 100 mM
ammonium bicarbonate/acetonitrile 50/50 for 5 min and pure acetonitrile for a
further 5 min. 50 μl of 12 ng/μl trypsin (Promega, Madison, WI) were added to
each gel piece and after 45 min at 4 °C the trypsin solution was replaced with
50 mM ammonium bicarbonate for 12 h at 37 °C. Tryptic peptides were then
extracted from the gel with 5% formic acid and dried by vacuum centrifugation.
Peptides were resuspended in 0.5% acetic acid and analyzed by LC-IT-MSMS.
For mass spectometry, an LCQ DECA XP-Plus ion trap mass spectrometer
(Thermo Electron, San José, CA) equipped with an in-house built micro-
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José, CA) was used. Samples were loaded in an in-house packed pre-column
(C18 resin, 5 μm particle size) placed before a C18 column packed in the
sprayer. Peptides were separated and eluted from the column with a 0.5% acetic
acid/acetonitrile gradient (from 0.5% acetic acid/acetonitrile 98/2 to 0.5% acetic
acid/acetonitrile 50/50 in 30 min, flow rate 1 μl/min). MS and MSMS spectra
acquired in a data dependent manner were searched against the SWISS-PROT
database using the TurboSequest software provided by the manufacturer.
2.6. RNA interference
For the RNA interference of human PRL-3 a specific small interfering RNA
(siRNA)was used (si1: 5′-TCTCGTTTCTCTTGGACAA-3′OnTarget 2′-hydroxyl,
annealed and desalted duplex—Dharmacon). The following siRNAswere used as
negative controls: Renilla luciferase: 5′-AAAAACATGCAGAAAATGCTG-3′;
GL2: 5′ CGTACGCGGAATACTTCGA 3′ (Dharmacon). HCT116 cells were
seeded in 6-well plates at 1.5×105 cells/well in complete McCoy's for 30%
confluence the next day. The following day, siRNA si1 were transfected at a final
concentration of 90 nM in 300 μl of Optimem Reduced Serum Medium (Invi-
trogen) in presence of Oligofectamine (Invitrogen). After transfection, cells were
incubated 4 h at 37 °C/5%CO2 after which time 3ml complete mediumwere added
and cells were further incubated for 20 h at 37 °C/5%CO2. Cells were collected at
24 h post-transfection or medium was replaced for longer incubation time.
HUVEC were seeded in 6-well plates at 3.5×105 cells/well in EGM me-
dium. After 8 h the cells were treated with 100 nM PMA (Phorbol 12-myristate
13-acetate; Sigma) in DMSO in EBM medium for 12 h at 37 °C/5%CO2 for
inducing the expression of endogenous PRL-3. siRNA si1 was added to the
culture at a final concentration of 10 nM in 900 μl of Optimem without serum in
presence of Lipofectamine 2000. After transfection, cells were incubated 4 h at
37 °C/5%CO2 after which time complete medium supplemented with PMA/Fig. 1. The phospho-protein pattern of HCT116 cells is affected by over-expression of
wild-type (wt, lanes 1,2,3) and mutants (D72A, lanes 4,5,6; D72A/C104S, lanes 7,8,9
were prepared at 24, 48 and 72 h post-transfection and 15 μg were loaded on 12.5% S
used at 1:1000 dilutions. B) Total protein extracts were prepared from HCT116 cells m
4,5,6) and mutants (D72A, lanes 7,8,9; D72A/C104S, lanes 10,11,12) PRL-3 constru
PAGE. The gel was stained with ProQ Diamond for phospho-protein pattern analysis
and C indicate the band whose intensity in the ProQ Diamond-stained gel appears dDMSO 100 nM was added and cells were further incubated for 20 h. Cells were
collected at 24 h post-transfection or medium was replaced for longer incubation
time. Unless otherwise specified, both HCT116 cells and HUVEC were treated
for 30 min at 37 °C/5%CO2 before collection with Sodium orthoVanadate
(Aldrich) and H2O2 at 0.1 mM final concentrations.
2.7. Quantitative real time RT-PCR analyses
Purification of total RNA was performed using RNeasy Miny kit (Qiagen)
following manufacturer's instruction Quantitative real time RT-PCR analyses were
performed with the ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) and threshold numbers observed using SDS 2.2.2 software.
The following primer set was used for RT-PCR amplification of endogenous
PRL-3mRNA:Forward 5′-AGGACGCCATCCAGTTCATC-3′; Reverse 5′-AGG-
TGAGCTGCTTGCTGTTA-3′; Probe 5′-CCAGAAGCGCCGCGGAGC-3′.
As internal control, Human 18S rRNA (Applied Biosystems) was used.
According to the manufacturer's instruction, a master mix (50 μl) of the following
reaction components was prepared to the indicated final concentration: 25 μl of 2×
Universal PCRMaster Mix (Applied Biosystems), 1.25 μl of 40× Multiscribe and
RNase Inhibitor Mix (Applied Biosystems), 90 nM of each forward and reverse
primer, 150 nM of probe, 10 μl (100 ng) of total RNA and the proper amount of
RNase-freewater. After an initial incubation at 48 °C for 30min and denaturation at
95 °C for 10 min, the following cycling conditions (40 cycles) were used:
denaturation at 95 °C for 15 s, annealing and elongation at 60 °C for 1 min.
2.8. PMA and TNF-α treatment of HUVEC
HUVEC were seeded in 6-well plates at 5×105 cells/well in EGM. The
following day, 100 nM PMA/DMSO, or DMSO alone, was added to the cells in
serum-free EBM2 and incubation continued for 24 h at 37 °C/5%CO2. For TNF-αwtPRL-3 but not of its catalytically inactive mutants. A) Western blot analysis of
) PRL-3 proteins in transiently transfected HCT116 cells. Total proteins extracts
DS-PAGE. Rabbit polyclonal antibody against wtPRL-3 expressed in E. coli was
ock-transfected (lanes 1,2,3) or transiently transfected with wild-type (wt, lanes
cts at 24, 48 and 72 h post-transfection and 40 μg were resolved on 7.5% SDS-
followed by (C) total protein staining by SyproRuby. The arrowheads in panel B
iminished upon wtPRL-3 over-expression.
Fig. 2. PRL-3 over-expression reduces phosphorylation of Ezrin-pTyr residues
and pThr567 in HCT116. Western blot analysis of Ezrin and Ezrin-
phosphorylated forms in HCT116 cells transiently transfected with wild-type
(wt, lane 2) andmutant PRL-3 constructs (D72A, lane 3; D72A/C104S, lane 4) in
comparison to mock-transfected cells (mock, lane 1). Total protein extracts were
prepared at 24 h post-transfection and 20 μg were loaded on 7.5% SDS-PAGE
for probing with α-Ezrin antibody (1:1000), α-pTyr(clone 4G12) (1:2000)
and α-Ezrin pTyr353 (1:1000). For probing with α-ERMpThr567 (1:300)
and α-Ezrin pTyr145 (1:300) 150 μg total proteins were loaded. Immunoblots
were developed by the enhanced chemioluminescence technique.
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37 °C/5%CO2 in EGM in the presence of 20 ng/ml recombinant human TNF-α
(R&D Systems) or vehicle alone (PBS containing 0.1% BSA).
2.9. PTPase assays
For FlagPRL-3 immunoprecipitation, 900 μg of total extract from FlagPRL-3
or mock-transfected cells not treated with orthoVanadate were incubated overnight
at 4 °C with 60 μl of Anti-Flag M2 affinity gel freezer-safe (Sigma) in lysis buffer.
Protein elution was performed under native condition by competition with 100 μg/
ml 3× Flag peptide (MDYKDHDGDYKDHDIDYKDDDDK; Sigma) at RT for
1 h in 180 μl Elution buffer (Tris 50 mM, pH 7, NaCl 100 mM, Triton 0.05%,
Glycerol 5%, TCEP 1 mM, DPTA 1 mM). The presence of wtPRL-3 was assessed
bywestern blot analysis and the total protein pattern ofmock and FlagPRL-3 eluted
extracts compared by silver-staining of SDS-gels.
The PTPase activity of the eluted FlagPRL-3 was assessed by incubating
70 μl of mock or FlagPRL-3 eluted extracts with diFMUP (6,8-difluoro-4
methylumbelliferyl phosphate) 100 μM in 80 μl final volume for 4 h at 37 °C. To
each reaction, 20 μl of Enzolyte reagent (AnaSpec) was added and the amount of
phosphate freed from the substrate quantified by spectrometry (A620 nm).
For endogenous phospho-Ezrin immunoprecipitation, 100 μg of total
extracts from orthoVandate-treated HCT116 were incubated overnight at 4 °C
with 30 μl of anti-PhosphoTyrosine (4G10) agarose-conjugate in lysis buffer
(Tris 20 mM, pH 7.5, NaCl 100 mM, Triton 1%, Glycerol 10%, EDTA 1 mM,
Okadaic acid 1 μM, SodiumPyrophosphate 10mM,NaF 20mM, Iodoacetic acid
5mM,DTT1mM, SodiumorthoVanadate 0.1mM,Complete). After incubation,
the agarose beads were washed three times in assay buffer (Tris 50 mM, pH 7,
NaCl 100 mM, Triton 0.05%, Glycerol 5%, TCEP 1 mM, DPTA 1 mM) and
incubatedwith 100 μl of FlagPRL3 or mock-immunoprecipitatedmaterial for 4 h
at 37 °C. The levels of Ezrin phospho-tyrosines and pThr567 affected by
incubation with FlagPRL-3 were analyzed by western blot, using Ezrin as
internal control. Image acquisition was performed with LAS-3000 (FUJIFILM)
and elaborated with Multigauge V2.2 (FUJIFILM).
3. Results
3.1. Identification of Ezrin as a cellular target of PRL-3
With the aim of identifying the PRL-3 molecular targets, we
transiently over-expressed in the colon cancer cell line HCT116
the wild-type PRL-3 (wt) and the two mutant proteins PRL3-
D72A (D72A) and PRL3-D72A/C104S (D72A/C104S), which
respectively displayed partially or completely abolished catalytic
activity, in order to observe differences in their phospho-protein
patterns. PRL-3 over-expression was monitored by western blot
analysis using a polyclonal antibody raised against the PRL-3
protein expressed in E. coli. For both the wt and mutant proteins,
maximal expression was observed at 24 h post-transfection, after
which time the expression level significantly decreased (Fig. 1A).
The differences between the phospho-protein pattern of total
protein extracts from HCT116 cells transiently transfected for the
expression of wt or mutant PRL-3 proteins were evaluated after
Phospho-staining of mono-dimensional SDS-PAGE gels
(Fig. 1B). A clearly different phospho-protein pattern was ob-
served in the cells over-expressing wtPRL-3 at 24 h post-
transfection (Fig. 1B), time at which the expression of the ectopic
protein was maximal. Particularly, phosphorylation of a band
migrating as an 80 kDa protein appeared heavily affected by
wtPRL-3 expression (lane 4) but not affected by expression of
PRL3-D72A mutant (lane 7) and of the double mutant D72A/
C104S (lane 10). Each lane of the gel contained essentially the
same amount of total protein loaded, as evidenced by SyproRuby
staining (Fig. 1C).The 80 kDa protein whose phosphorylation level diminished
in the PRL-3 over-expressing cells was identified by LC-IT-
MSMS as corresponding to Ezrin (Swiss-Prot # P15311). PRL-3
over-expression only affected the phosphorylation state of Ezrin,
but not its level of expression, which remained unchanged as
also indicated by western blots probed with an Ezrin-specific
antibody (Fig. 2).
Ezrinwas confirmed as the proteinwhose phosphorylation state
was the greatest affected by over-expression of PRL-3 by 2-D
DIGE (2-D Difference Gel Electrophoresis) experiments com-
bined with LC-IT-MSMS (data not shown. In 2-D gels Ezrin was
resolved as a train of nine spots corresponding to differently
modified forms of the protein, three of which resulted to be not
phosphorylated and six phosphorylated. Upon PRL-3 over-
expression, a reduction of the phosphorylated forms of Ezrin and
an increase of the non-phosphorylated ones were clearly noticed
(data not shown).
3.2. PRL-3 over-expression affects the phospho-tyrosine
pattern of Ezrin and causes dephosphorylation of pThr567
Ezrin, together with Radixin andMoesin, constitutes the ERM
(Ezrin/Radixin/Moesin) protein family whose main function is to
provide a regulated bridge between cell surface receptors and
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Thr567 and the phosphorylation status of a number of Tyr and
Ser residues regulates its involvement in different cellular pro-
cesses [23].
We investigated whether PRL-3 acts on pTyr-Ezrin by
western blot analysis comparing HCT116 cells with or without
over-expression of wtPRL-3 and probing with an antibody
generically recognizing pTyr residues. As evident from Fig. 2
(α-pTyr), a remarkable down-regulation of the Ezrin tyrosine-
phosphorylation level was observed upon ectopic over-expres-
sion of PRL-3 (compare lanes 1 and 2).
While the clear effect on the overall phospho-tyrosine pattern
of Ezrin observed is presumably caused by the dephosphoryla-
tion of several residues, the lack of commercial antibodies
directed against each of the known phospho-tyrosine residues
made it difficult to precisely define which residues are affected
by PRL-3 action. We focused, therefore, our interest on two of
the most studied pTyr residues of Ezrin, pY353 and pY145
which are both involved in several processes such as cell
motility, cell spreading and proliferation [24,25]. Since PRL-3 is
implicated in cell migration ([15] and E. Forte, unpublished
results), both Ezrin-pY353 and pY145 might be possible targets
of PRL-3. Hence, we analyzed the effect of the ectopic ex-
pression of wtPRL-3 on these residues using commercial anti-Fig. 3. Endogenous PRL-3 suppression by RNA interference in HCT116 only influen
endogenous PRL-3 mRNA level at 24, 48 and 72 h post-transfection with 90 nM si1
silenced cells is expressed relative to its level in mock-transfected cells, arbitrary set to
HCT116 cells. 100 μg of total protein extracts from cells mock-transfected (lane 1) or
transfection were resolved on 12.5% SDS-PAGE probed with α-PRL-3 antibody. T
mock-transfected cells. C) Total protein extracts were prepared at 24, 48 and 72 h af
were loaded on 7.5% SDS-PAGE for probing with α-Ezrin, α-pTyr (clone 4G12) and
pThr567. D) Down-regulation of PRL-3 caused a 4.4-fold increase of the Ezrin-pThr5
observed at 24 h and 48 h post-transfection, respectively, relative to its level in moc
sample.bodies specific for Ezrin-pY353 and pY145. As clearly shown in
Fig. 2, a marked effect of wtPRL-3 over-expression (lane 2), but
not of its mutants (lanes 3 and 4), on the phosphorylation state of
both Ezrin-pY353 and pY145 was observed, clearly pointing to
these residues as possible target sites of PRL-3.
Phosphorylation of Thr567 in ERM proteins is critical for the
activation of the protein triggering the open conformation com-
petent for actin binding and correct localization to the membrane
[26]. Western blot analysis with an antibody directed against
ERM-pThr567 (Fig. 2) showed that phosphorylation at T567
was weakened by wtPRL-3 over-expression (lane 2) while no
effect was observed upon over-expression of the inactive protein
forms (lanes 3 and 4). The antibody directed against pThr567 is
not specific for Ezrin being the peptide containing Thr567
common to all the three ERM proteins. Consequently, radixin
is also observed in the mono-dimensional gel system probed
with this antibody (Fig. 2). However, it is interesting to note that
only the phosphorylation state of Ezrin-Thr567 appeared to be
affected by wtPRL-3 over-expression since the intensity of the
band corresponding to radixin is almost unchanged with respect
to themock-transfected sample (Fig. 2, lanes 1 and 2). This result
not only indicated Thr567 as a further target site of PRL-3 on
Ezrin but also suggested PRL-3 action specifically directed
against Ezrin.ces the phosphorylation state of Ezrin-pThr567. A) Effect of PRL-3 silencing on
RNAs, as determined by quantitative Real Time PCR. PRL-3 mRNA amount in
1. B) Western blot analysis of the endogenous PRL-3 protein in PRL-3 silenced
transfected (lane 2 and 3) with the si1 RNA at 24 h (lane 2) and 72 h (lane 3) post-
he arrow indicates the band corresponding to the endogenous PRL-3 protein in
ter mock-transfection (lanes 1,2,3) or PRL-3 silencing (lanes 4, 5, 6) and 20 μg
α-GAPDH (1:1000). 150 μg total proteins were loaded for probing with α-ERM-
67 phosphorylation level at 72 h post-transfection while no or poor increase was
k-transfected cells. Values were normalized to the amount of total Ezrin in each
Fig. 4. Increased expression of PRL-3 in HUVEC upon PMA treatment
produced dephosphorylation of Ezrin-pThr567. Confluent HUVEC were treated
for 24 h with DMSO/PMA 100 nM (lane 2) or mock-treated with DMSO alone
(lane 1). For reversion of PRL-3 induction, HUVEC pre-incubated with PMA
were transfected with the PRL-3 specific silencing RNA si1 (10 nM) (lane 4) or
mock-transfected (lane 3) and further incubated in the presence of PMA for 24 h.
Total protein extracts were resolved on 7.5% SDS-PAGE and transferred to
nitrocellulose membranes for evaluating the amount of PRL-3, total Ezrin and its
phosphorylated forms. GAPDH was used as a reference protein. The bands
corresponding to PRL-3 and Ezrin are indicated by arrows.
Fig. 5. PMA treatment of HUVEC cells abrogates the effect of TNF-α in
enhancing phosphorylation of Ezrin-Thr567. A) HUVEC that were (lane 3) or
were not (lanes 1 and 2) treated with PMA/DMSO were further incubated with
20 ng/ml TNF-α (lanes 2 and 3) or vehicles alone (PBS/0.1% BSA and DMSO)
(lane 1). Total Ezrin, Ezrin-pThr567 and PRL-3 were examined by western blot.
B) TNF-α treatment caused 30% increase of the phosphorylation level of Ezrin-
Thr567, while the enhanced expression of PRL-3 in cells simultaneously treated
with TNF-α and PMA caused 80% reduction with respect to its degree of
phosphorylation inmock-treated cells set to 100%, as derived from quantification
of the corresponding bands in the immunoblots. Values were normalized to the
amount of total Ezrin in each sample.
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of Ezrin-Thr567
Down-regulation of the endogenous PRL-3 mRNA in
HCT116 cells was achieved by RNA interference in order to
confirm Ezrin as a specific cellular target of PRL-3. Transfec-
tion of HCT116 cells with PRL-3-directed siRNA oligonucleo-
tides produced a significant reduction of the PRL-3 mRNA.
Only about 25% of the endogenous PRL-3 mRNAwas present
24 h post-transfection, while this amount increased to 35% at
72 h post-transfection, as measured by Real Time PCR
(Fig. 3A). The reduction of PRL-3 mRNA 24 h post-transfection
produced the almost complete disappearance of the PRL-3
protein, as judged by western blot using a polyclonal antibody
directed against the PRL-3 protein expressed in E. coli, which
also recognized unspecific bands (Fig. 3B). This low level was
maintained up to 72 h post-transfection, despite the increase of
the mRNA level (Fig. 3B, lane 3).
Variations in the overall phospho-tyrosine level and in the
phosphorylation state of Ezrin-Thr567 were monitored by
western blot analysis of total extracts from cells transfected
with the siRNA (Fig. 3C, lanes 4 to 6) in comparison to those
from mock-transfected cells (Fig. 3C, lanes 1 to 3). As shown in
Fig. 3C, PRL-3 down-regulation did not appear to affect the
overall tyrosine-phosphorylation level of Ezrin. In contrast, an
increased level of phosphorylation at Ezrin-Thr567 was
observed in cells transfected with siRNA 72 h post-transfection
(Fig. 3C, lane 6). The observation that higher levels of Ezrin-
pThr567 were only observed at 72 h post-transfection might
imply that Ezrin-pThr567 has to accumulate to be detectable by
western blot. These results confirmed Ezrin as a specific PRL-3
target and pointed to Thr567, one of the most critical residues for
regulation of Ezrin functions, as the main residue hit by PRL-3action. On the other hand, the unaltered levels of Ezrin-tyrosine
phosphorylation might either suggest that the effect observed
upon ectopic PRL-3 over-expression was unspecific or that only
high levels of PRL-3 expression, such as those possibly reached
in metastatic cells, are needed to affect pTyr levels.
3.4. PRL-3 affects only Ezrin-pThr567 in endothelial cells
A significant increase of PRL-3 expression in endothelial
cells upon PMA treatment has been recently reported [27]
though the PRL-3 expression level hardly reaches that obtained
in HCT116 cells by ectopic over-expression. Therefore, we
sought to verify whether the induction of the PRL-3 endogenous
gene might reproduce the same effects on the Ezrin phosphor-
ylation status observed by ectopic over-expression in HCT116
cells. We decided to use HUVEC (Human Umbilical Vas-
cular Endothelial Cells) which express a very low PRL-3 level
in standard condition but that showed a significant increase
of PRL-3 expression upon PMA treatment (100 nM) (Fig. 4,
α-PRL-3, compare lanes 1and 2). Notably, neither variation of
the phosphorylation status of Ezrin-pTyr145 and Ezrin-pTyr353
nor that of the Ezrin global tyrosine-phosphorylation status was
observed by probing cell extracts with the specific antibodies
(Fig. 4, lanes 1 and 2). The only Ezrin residue whose phos-
phorylation level appeared affected by the increased expression
Fig. 6. Ezrin-pThr567 is a substrate of the PRL-3 enzyme. For in vitro PTPase assays using PRL-3 as enzyme and phosphorylated Ezrin as substrate, a FlagPRL-3
protein was immunoprecipitated from transiently transfected HCT116 cells with Anti-Flag M2 resin followed by native elution competing with a Flag peptide. As a
control, mock-transfected cells were subjected to the same procedure. A) The presence of PRL-3 in native total extracts from FlagPRL-3- (lane 2) and mock- (lane 1)
transfected cells was assessed by immunoblotting and B) the total protein pattern of mock (lane 1) and FlagPRL-3 (lane 2) extracts eluted from the anti-Flag M2 resin
were compared by silver-staining of SDS-gels. C) In vitro phosphatase assays using DiFMUP as substrate confirmed the presence of phosphatase activity especially in
the FlagPRL-3 eluted sample (bar 2) with respect to mock (bar 1). Phosphatase activity is expressed as the concentration of free phosphate released upon 4 h incubation
at 37 °C. D) Endogenous phospho-Ezrin was immunoprecipitated from total extracts (T, lane 1) of HCT116 cells with anti-Phospho-tyrosine (4G10) agarose-conjugate
and a negligible amount still remained in the unbound material (S, lane 2). The agarose-bound phospho-Ezrin was either not incubated (to, lane 3) or incubated for 4 h
at 37 °C either in reaction buffer alone (lane 4) or with mock (lane 5) or FlagPRL-3 (lane 6) immunoprecipitated samples. The level of global Ezrin-pTyr and pThr567
in each sample was analyzed by western blot, using total Ezrin as internal control. E) Incubation with FlagPRL-3 produced 70% reduction of phosphorylation of Ezrin-
Thr567 (bar 6) with respect to its level in the initial material (bar 3) set to 100%, as judged by quantification of immunoblots using total Ezrin as internal reference. Bars
numbers correspond to lanes numbers in panel D.
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exclude the possibility that the effect observed might result from
PMA action other than PRL-3 up-regulation, we transfected
cells with the PRL-3-directed siRNA si1 following PMA
treatment. As shown in Fig. 4 (α-PRL-3, lanes 3–4), transfection
of the silencing RNA completely counteracted PMA action re-
establishing the PRL-3 expression level of naïve HUVEC
(lane 1). The effect on the phosphorylation status of Ezrin-
Thr567 also appeared abolished being the level of pThr567 in
the silenced cells (Fig. 4,α-ERMpThr567, lane 4) comparable to
that of untreated HUVEC (lane 1). PRL-3 mRNA silencing in
the PMA-treated cells did not alter the tyrosine-phosphorylation
state of Ezrin (Fig. 4, lanes 1, 3, 4).
Additional experiments were performed to verify whether
PMA induction of PRL-3 expression in endothelial cells could
counteract the known effect of TNF-α in enhancing ERM-
Thr567 [28]. While TNF-α treatment of HUVEC caused an
increase in the level of Ezrin-pThr567 (Fig. 5A, compare lanes 1
and 2), the enhanced expression of PRL-3 in cells simulta-
neously treated with TNF-α and PMA caused a great reduction
of Ezrin-pThr567 level (Fig. 5A, lane 3), which was estimated
as about 20% of that present in untreated HUVEC (Fig. 5B).These data strongly indicate that PRL-3 is involved in the
dephosphorylation of Ezrin-Thr567 in endothelial cells.
3.5. Phosphorylation of Thr567 is decreased by PRL-3 in vitro
The experiments described above clearly suggested Ezrin, and
particularly Ezrin-pThr567, as a specific cellular target of the
PRL-3 phosphatase. However, there were no indication of
whether the effects observed derived from a direct action of
PRL-3 on Ezrin or, on the contrary, result from its activity toward
a second phosphatase (or other effectors) that, in turn, affects
Ezrin phosphorylation status. In order to clarify this point, we
devised an experiment aimed to measure in vitro the phosphatase
activity of PRL-3 extracted from cells using immunoprecipitated
Ezrin as a substrate. To this end, an N-terminally flagged PRL-3
protein (FlagPRL-3) was over-expressed in HCT116 cells by
transient transfection (Fig. 6A) and partially purified 24 h after
transfection by immunoprecipitation with an α-Flag antibody
followed by elution from the α-Flag-resin with high excess of a
Flag peptide. As a control, mock-transfected cells were treated in
the sameway of those over-expressing FlagPRL-3 and the pattern
of the proteins eluted from mock and FlagPRL-3 containing
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Fig. 6B, the proteins eluted from theα-Flag-resin were essentially
the same in both the extracts with FlagPRL-3 as the only band,
among the many others, that was clearly absent in the partially
purified material from mock-transfected cells. To exclude the
possibility that phosphatases other than FlagPRL-3 could be
present among the contaminating proteins, the phosphatase
activity of partially purified extracts from mock and FlagPRL-3
transfected cells was measured on the generic phosphatase
substrate DiFMUP. The experiment reported in Fig. 6C demon-
strates that a significant phosphatase activity was contained in the
FlagPRL-3 preparation but was almost absent in the control
extract. Ectopic over-expression in HCT116 of FlagPRL-3 still
produced reduction of both Ezrin tyrosines and Thr567
phosphorylation levels (not shown), thus excluding a possible
negative effect of the Flag peptide.
Because of the low immunoprecipitation efficiencies of all
the commercial α-Ezrin antibodies tested, we decided to use an
agarose-conjugated α-pTyr antibody to enrich Ezrin from
HCT116 cells. To preserve the complete phosphorylation status
of Ezrin on Tyr and Thr residues, cells were treated with H2O2/
orthoVanadate and extracts prepared in the presence of common
phosphatases inhibitors. As shown in Fig. 6D (lanes 1, 2, 3),
Ezrin was efficiently enriched on the α-pTyr/agarose beads
(Fig. 6D, α-Ezrin) and, in the conditions adopted, the phos-
phorylation status of both Tyrosine residues and Ezrin-Thr567
was preserved (Fig. 6D, α-pTyr and α-ERM-pThr567). Fol-
lowing extensive washing to get rid of the phosphatase inhibitors
present in the cell extracts, the Ezrin/α-pTyr beads were
incubated for 4 h at 37 °C either alone or in the presence of
partially purified FlagPRL-3 or control preparation. Interest-
ingly, while no effect was observed on the global tyrosine-
phosphorylation status of Ezrin (Fig. 6D, lanes 4,5,6, α-pTyr), a
remarkable reduction of the phosphorylation level associated to
Ezrin-Thr567 was obtained upon incubation with FlagPRL-3
(Fig. 6D, lanes 4,5,6, α-ERMpThr567) which was estimated as
corresponding to about 30% of that of the untreated or mock-
treated samples (Fig. 6E). These results might indicate Ezrin-
pThr567 as a specific and direct target of PRL-3.
4. Discussion
In this study we present evidence pointing to Ezrin as a
specific and direct cellular target of PRL-3. With the aim of
identifying its substrate(s), we decided to use HCT116 cells
since PRL-3 expression level has been observed as being
particularly enhanced in colon cancer metastasis and HCT116
were thought to contain the PRL-3 cellular target(s) being a
colon cancer cell line with metastatic potential. In addition, as
the expression level of the endogenous PRL-3 protein in
HCT116 is limited if compared to other colon cancer cell lines
([27] and data not shown), we thought that ectopic over-
expression of PRL-3 in this cell line might have produced a
notable modification of its substrate(s) thus allowing its
identification. Indeed, Ezrin was identified in HCT116 among
the cellular proteins whose phosphorylation level resulted
affected by ectopic over-expression of wtPRL-3, but not of itscatalytically inactive mutants. That Ezrin is in fact the major
target of PRL-3 in HCT116 has been also demonstrated by 2-D
DIGE (data not shown), which has been described as a powerful
technique for monitoring changes in the protein phosphoryla-
tion pattern. In this case, however, less pronounced alterations
of the phosphorylation pattern or expression level of other
proteins were also observed. The results of the 2-D DIGE
experiments will be described in deep detail elsewhere.
The identification of Ezrin as the predominant target of PRL-3
action in HCT116 cells is of particular interest because of the
involvement of the ERM family members (Ezrin-Radixin-
Moesin) in a number of cellular processes, such as cell survival,
proliferation, invasiveness and migration, where PRL-3 also
takes part [23]. Moreover, Ezrin expression correlates with
tumor thickness and level of invasion and it might play a role in
the metastatic progression of several tumors [29,30]. The
biological role of Ezrin in the cascade of tumor growth and
metastasis is, however, not yet completely understood but it is
known that Ezrin resides at the nexus of several pathways
which regulate cellular behavior influencing metastatic poten-
tial [29]. Furthermore, its action is controlled by the phos-
phorylation status of several Tyr, Ser and Thr residues and
while the many kinases involved are well studied, little is
known about the phosphatases implicated [31–33].
In HCT116 cells, Ezrin is one of the most abundant and
heavily phosphorylated proteins, especially at the level of
tyrosine residues. For this reason, the finding that PRL-3 over-
expression caused a heavy dephosphorylation of pTyr-Ezrin
and, as a consequence, also of the two specific tyrosines ana-
lyzed, Tyr353 and Tyr145, might well suggest an unspecific
action of PRL-3 on Ezrin tyrosine-phosphorylation levels.
Moreover, the observation that suppression of endogenous PRL-
3 in HCT116 cells by RNA interference did not appear to affect
the tyrosine-phosphorylation state of Ezrin, seems to exclude a
role of PRL-3 in the balance of Ezrin tyrosine-phosphorylation
pattern. However, the possibility exists that Ezrin-tyrosine
residues might only be affected by high expression levels of
PRL-3, such as those possibly reached in cancer metastasis,
while lower PRL-3 expression does not.
As well as the other ERM proteins, Ezrin exists in the cyto-
plasm in an inactive, “closed”, conformation with N-terminal to
C-terminal association within the protein or with other ERM
members [22]. Upon threonine and tyrosine phosphorylation,
Ezrin assumes an active, “open”, conformation, and bridges
F-actin directly or indirectly to the cell membrane [22]. Thr567
plays a major role in Ezrin activity since its phosphorylation is
the crucial part of the process that triggers the active “open”
conformation of the molecule [26]. Notably, as a further con-
sequence of wtPRL-3 ectopic over-expression, the degree of
Ezrin-Thr567 phosphorylation also appeared greatly dimin-
ished. That the PRL-3 effect might be specific was suggested
by the observation that the phosphorylation state of the cor-
responding Thr residue in Radixin did not appear altered by
PRL-3 over-expression, though contained in a sequence that is
well conserved among the ERM proteins [31]. Indeed, the RNA
interference experiments, where an enhancement of Ezrin-
pThr567 abundance was observed upon endogenous PRL-3
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addition, the in vitro PTPase experiments, where immunopre-
cipitated Ezrin was subjected to dephosphorylation by an im-
munoprecipitated PRL-3 carrying an N-terminal Flag epitope
(FlagPRL-3), seem to suggest Ezrin-pThr567 as a direct sub-
strate of PRL-3, though the possibility cannot be excluded that,
in these experiments, the PRL-3 action on Ezrin might have been
mediated by other phosphatase(s), direct target(s) of PRL-3, co-
immunoprecipitated by the α-pTyr antibody used to enrich Ezrin
from the cell extracts. Intriguingly, however, Ezrin-pTyr residues
were not affected. Taken together, these results point to Ezrin-
pThr567 as a specific cellular target of the PRL-3 phosphatase
activity. Little, if anything, is known about the substrate pre-
ferences of PRL-3 or its close homologues PRL-1 and 2, though
they can be classified by structure-based sequence alignments as
dual specificity PTPases [34] and the results of our in vitro
PTPase assays might support this classification. The observation
that in the in vitro PTPase assays we noted PRL-3 action only on
Ezrin-pThr567 does not exclude the possibility that, on other
proteins, PRL-3 might act on pTyr residues. On the other hand,
besides not being direct substrates of PRL-3, our failure to ob-
serve direct dephosphorylation of Ezrin-pTyr residuesmight also
have additional explanations: i) the α-pTyr antibody used to
enrich Ezrin from the cell extracts might have impeded recog-
nition of the pTyr residues, in contrast with our assumption
that statistically, most, if not all, of them could have been ac-
cessible to the enzyme; ii) in the hypothesis that very high levels
of PRL-3 are needed for Ezrin-pTyr dephosphorylation to occur,
as suggested above, the enzyme might have a very low affinity
toward Ezrin-pTyr residues, such that the possibly low amount of
active protein in the immunoprecipitated material is not suf-
ficient to catalyze dephosphorylation; iii) accessory factor(s) or
previous modification of the target protein are also required but
are not present in the in vitro reaction with the consequence that
the in vitro assay does not recapitulate the in cell process.
Besides reinforcing the suggestion of Ezrin-pThr567 as a
target of PRL-3, the observation that enhancement of expression
of endogenous PRL-3 by PMA stimulation of HUVEC produces
dephosphorylation of Ezrin-pThr567 is of particular interest
because of the possible role played by PRL-3 in triggering
angiogenesis and establishing the microvasculature needed for
tumor survival and progression [16,18,27]. In endothelial cells,
phosphorylation of Ezrin-Thr567 plays a central role in
promoting the cellular responses to TNF-α treatment, including
inhibition of proliferation and impaired ability to progress through
the cell cycle [28,35]. In this light, dephosphorylation of Ezrin-
Thr567 guided by PRL-3 might likely have an opposite effect by
enhancing cell proliferation and therefore promoting EC
proliferation and angiogenesis. Indeed, PMA stimulation of
ECs has been shown to enhance invasion, tube formation and
proliferation and PRL-3 was reported among the 10 genes with
the largest increase of expression on PMA treatment [27]. In
addition, PRL-3 was found in the endothelial cells of tumor
vasculature, regardless of tumor source [8] and as one of the genes
predominately expressed in the vasculature of invasive breast
cancer [18]. It is noteworthy that in PMA-stimulated HUVEC
PRL-3 only affected phosphorylation of Ezrin-pThr567 with noappreciable effect on the tyrosine-phosphorylation levels. In
HUVEC, the PRL-3 level upon PMA induction is still well below
that reached by ectopic over-expression, thus strengthening the
suggestion that only very high PRL-3 levelsmight affect tyrosines
phosphorylation.
On the assumption that aberrant PRL-3 expression inmetastatic
cells does affect both global Ezrin-tyrosine phosphorylation and
Thr567, the heavy dephosphorylation produced would likely
culminate in Ezrin inactivation. Interestingly, recent studies report
increased RhoA, RhoC and Src activities in cells expressing
exogenous PRL-3, as well as decreased Rac1 [19,20]. Both RHO-
family proteins and Src kinase are fundamental in controllingEzrin
function [25,36,37] and deregulation of their activity can promote
tumor progression and metastasis [38,39] by altering actin
cytoskeleton organization. Notably, small GTPase Rho controls
ERM function by phosphorylating the C-terminal Thr, Thr567 in
the case of Ezrin, required for ERM to adopt an active
conformation. In turn, active ERMs control small GTPase Rho
activity by recruiting both their positive (GEFs) and negative
(RhoGDI) regulators [40]. It is conceivable that inactivation of
Ezrin by PRL-3 action would promote release of Rho regulators
thus explaining the increment of RhoA and RhoC activities, as
well as the decreased Rac1, observed by Fiordalisi et al. [19].
Tyrosine kinase Src directly promotes phosphorylation of Tyr477
and Tyr145 in active Ezrin and the latter modification is linked to
signaling events leading to epithelial cell spreading and prolifera-
tion [25,37]. However, for Tyr145 phosphorylation by Src to
occur, Ezrin must be in an open, active conformation and binding
of the Src-SH2 domain to phosphorylated Ezrin-Tyr190 is an
additional fundamental prerequisite. It is likely, that in cells where
PRL-3 is abnormally expressed, because of Ezrin inactivation, Src
activity moves towards other targets initiating signal pathways
involving ERK1/2, STAT3 and P130CAS which contribute to the
increased cell invasion and migration properties found in cells
over-expressing PRL-3 [20]. Therefore, loss of active Ezrin
prompted by PRL-3 might contribute to tumor progression and
development by deregulating RHO GTPase and Src activities.
We have provided evidence that Ezrin is a specific and direct
cellular target of PRL-3. Although PRL-3 over-expression in the
HCT116 colon cancer cell line appeared to affect Ezrin
phosphorylation status at both tyrosine residues and Thr567,
silencing experiments, combined to in vitro dephosphorylation
assays, suggested that PRL-3 more directly acts on Ezrin-Thr567
indicating this enzyme as one of the phosphatases that function as
modulators of Ezrin activity through regulation of the phosphor-
ylation state of this crucial residue. Furthermore, the same effect
on pThr567, but not on pTyr residues, was observed in endothelial
cells confirming pThr567 as a specific substrate of PRL-3. We
propose dephosphorylation of Ezrin-pThr567 by PRL-3 as a
mean through which this phosphatase exerts its function in
supporting new vasculature formation for tumor survival and
progression, though the understanding of the precise molecular
mechanism warrants further investigation. Moreover, we suspect
that the aberrant expression of PRL-3 in metastatic cells will
produce heavy dephosphorylation of Ezrin which might ulti-
mately lead to Ezrin inactivation and promotion of the molecular
processes at the basis of metastasis progression.
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